Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6623
Source ID: NCT06557811
Associated Drug: Semaglutide
Title: Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
Acronym: SemaFatCard
Status: NOT_YET_RECRUITING
Study Results: NO
Results:
Conditions: Diabetic Patients|Acute Myocardial Infarction
Interventions: DRUG: Semaglutide
Outcome Measures: Primary: Measurement of pericardial adipose tissue at 180 days, Measurement of pericardial adipose tissue (cm³), 180 days|Measurement of the fat attenuation index at 180 days, Measurement of the fat attenuation index (Hounsfield units (HU)), 180 days|Measurement of the perivascular adipose tissue attenuation index at 180 days, Measurement of the perivascular adipose tissue attenuation index (Hounsfield units (HU)), 180 days | Secondary: Determination of metabolic marker levels fasting blood glucose, Determination of metabolic marker level: fasting blood glucose (mg/dL), 180 days|Determination of metabolic marker levels HbA1c, Determination of metabolic marker level: HbA1c (%), 180 days|Determination of metabolic marker levels Insulin, Determination of metabolic marker level: Insulin (µU/mL), 180 days|Determination of metabolic marker levels HOMA-IR, Determination of metabolic marker level:HOMA-IR, 180 days|Determination of metabolic marker levels total cholesterol and fractions, Determination of metabolic marker levels:total cholesterol and fractions (mg/dL), 180 days|Determination of metabolic marker levels uric acid, Determination of metabolic marker levels:uric acid (mg/dL), 180 days|Determination of metabolic marker levels TSH, Determination of metabolic marker levels:TSH (µUI/mL), 180 days|Determination of metabolic marker levels free T4, Determination of metabolic marker levels: free T4 (ng/dL), 180 days|Determination of complete blood count with platelet count, Determination of complete blood count: Hemoglobin (g/dL), 180 days|Determination of complete blood count, Determination of complete blood count: Hematocrit (%), 180 days|Determination of platelet count, Determination of platelet count (x10\^3/µL), 180 days|Determination of cardiac marker levels Troponin I, Measure of cardiac marker level: Troponin I (ng/mL), 180 days|Determination of cardiac marker levels CK-MB, Measure of cardiac marker level: CK-MB (ng/mL), 180 days|Determination of cardiac marker levels C-Reactive Protein, Measure of cardiac marker level: C-Reactive Protein (mg/L), 180 days|Determination of cardiac marker levels Interleukin 6, Measure of cardiac marker level:Interleukin 6 (pg/mL), 180 days|Determination of cardiac marker levels NT-proBNP, Measure of cardiac marker level: NT-proBNP (pg/mL), 180 days|Determination of anthropometric measurements body mass index, Determination of anthropometric measurement: body mass index (kg/m2), 180 days|Determination of anthropometric measurements Neck Circumference, Determination of anthropometric measurement: Neck Circumference (cm), 180 days|Determination of anthropometric measurements Body Weight, Determination of anthropometric measurement: Body Weight (kg), 180 days|Determination of anthropometric measurements Abdominal Waist, Determination of anthropometric measurement: Abdominal Waist (cm), 180 days|Determination of anthropometric measurements Waist-to-Height Ratio, Determination of anthropometric measurement:Waist-to-Height Ratio, 180 days|Determination of anthropometric measurements Blood Pressure, Determination of anthropometric measurement: Blood Pressure (mmHg), 180 days|Determination of anthropometric measurements Heart Rate, Determination of anthropometric measurement:Heart Rate (bpm), 180 days
Sponsor/Collaborators: Sponsor: University of Sao Paulo General Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 88
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
Start Date: 2024-09-01
Completion Date: 2026-09-01
Results First Posted:
Last Update Posted: 2024-08-26
Locations: ARO (Academic Research Organization), São Paulo, SP, 05403-900, Brazil
URL: https://clinicaltrials.gov/show/NCT06557811